Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197185 | 0.91 | KMT2A (0.39) | CNR1 | |
| SCHEMBL16196970 | 0.90 | MAOB (0.36) | MCHR1MAOBFPR3FPR2RXFP1 | |
| SCHEMBL16197479 | 0.83 | RXFP1 (0.38) | MAOBRXFP1 | |
| SCHEMBL16196831 | 0.82 | MAOB (0.36) | MAOBHTR1ARXFP1 | |
| SCHEMBL16196907 | 0.82 | KMT2A (0.36) | CNR1 | |
| SCHEMBL16197632 | 0.81 | F10 (0.39) | — | |
| SCHEMBL30203112 | 0.80 | PPARD (0.36) | FPR2RXFP1 | |
| SCHEMBL16196958 | 0.80 | ALDH1A1 (0.41) | MAOBRXFP1 | |
| SCHEMBL16197188 | 0.80 | SMN1; SMN2 (0.39) | MAOBHTR1ARXFP1 | |
| SCHEMBL17558003 | 0.78 | AKR1B1 (0.39) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663495-B2 | Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | YUHAN CORPORATION (KR) | 2017-05-30 | — | — | US | disclosed |
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2016-03-10 | — | — | US | disclosed |
| EP-2989093-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Yuhan Corporation (KR) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014175621-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068515-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GPR119, GPR88, GCGR | MCHR1 962/4885MAOB 4104/4885HTR1A 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.